Ausführliche Literaturliste
Publikationen 2002
Publikationen 2003
Publikationen 2004
Publikationen 2005
Publikationen 2006
Publikationen 2007
Publikationen 2002
Bai RY, Koester C, Ouyang T, Hahn SA, Hammerschmidt M, Peschel C, Duyster J. SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol 2002;4:181-90
Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S, Tybulewicz VL, Peschel C, Duyster J. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem. 2002;277:12437-45.
Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer. 2002;9:33-44
Charbord P, Oostendorp R, Pang W, Herault O, Noel F, Tsuji T, Dzierzak E, Peault B. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissues. Exp Hematol. 2002;30:1202-10.
Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J, Peschel C. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 2002;16:327-34
Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 2002;99:1320-1326.
Fruehauf S, Veldwijk MR, Berlinghoff S, Basara N, Baum C, Flasshove M, Hegewisch-Becker S, Kroger N, Licht T, Moritz T, Hengge UR, Zeller WJ, Laufs S. Gene therapy for sarcoma. Cells Tissues Organs. 2002;172:133-44.
Fuchs M, Hutzler P, Brunner I, Schlegel J, Mages J, Reuning U, Hapke S, Duyster J, Hirohashi S, Genda T, Sakamoto M, Überall F, Höfler H, Becker KF, Luber B. Motility enhancement by tumor-derived mutant e-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors. Exp Cell Res. 2002;276:129-41.
Harzenetter MD, Keller U, Beer S, Riedl C, Peschel C, Holzmann B. Regulation and function of the CGRP receptor complex in human granulopoiesis. Exp Hematol. 2002;30:306-12.
Hoepfl J, Miething C, Grundler R, Gotze KS, Peschel C, Duyster J. Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia. 2002;16:1584-88.
Jahn T, Seipel P, Coutinho S, Urschel S, Schwarz K, Miething C, Serve H, Peschel C, Duyster J. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene. 2002;21:4508-20.
Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol. 2002;22:979-91.
Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia. 2002;16:846-54.
Keller U, Götze KS, Duyster J, Schmidt B, Rose-John S, Peschel C. Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors. Leukemia. 2002;16:2122-28.
Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med. 2002;8:631-37.
Kusadasi N, Oostendorp RA, Koevoet WJ, Dzierzak EA, Ploemacher RE. Stromal cells from murine embryonic aorta-gonad-mesonephros region, liver and gut mesentery expand human umbilical cord blood-derived CAFC(week6) in extended long-term cultures. Leukemia. 2002;16:1782-90.
Licht T, Haskins M, Henthorn P, Kleiman SE, Bodine DM, Whitwam T, Puck JM, Gottesman MM, Melniczek JR. Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A. 2002;99:3123-28.
Licht T, Peschel C. Restoration of transgene expression in hematopoietic cells with drug-selectable marker genes. Curr Gene Ther. 2002;2:227-34.
Licht TR, Laugesen D, Jensen LB, Jacobsen BL. Transfer of the pheromone-inducible plasmid pCF10 among Enterococcus faecalis microorganisms colonizing the intestine of mini-pigs. Appl Environ Microbiol. 2002;68:187-93.
Lordick F, Gundel H, von Schilling C, Würschmidt F, Leps B, Sendler A, Schüssler J, Brandl T, Peschel C, Sellschopp A. [Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]. Med Klin. 2002;97:449-54.
Löhr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin Exp Immunol. 2002;130:107-14.
Meyer zum Büschenfelde C, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002;62:2244-47.
Oostendorp RA, Medvinsky AJ, Kusadasi N, Nakayama N, Harvey K, Orelio C, Ottersbach K, Covey T, Ploemacher RE, Saris C, Dzierzak E. Embryonal subregion-derived stromal cell lines from novel temperature-sensitive SV40 T antigen transgenic mice support hematopoiesis. J Cell Sci. 2002;115:2099-108.
Oostendorp RA, Harvey KN, Kusadasi N, de Bruijn MF, Saris C, Ploemacher RE, Medvinsky AL, Dzierzak EA. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood. 2002;99:1183-89.
Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grunewald K, Poewe W, Gastl G. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol. 2002;117:623-25.
Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100:3741-48.
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
Scheidhauer K, Wolf I, Baumgartl HJ, von Schilling C, Schmidt B, Reidel G, Peschel C, Schwaiger M. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2002;29:1276-82.
von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487-91.
von Schilling C. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? Against. Eur J Nucl Med Mol Imaging. 2002;29:1254-56.
Wölfl M, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol. 2002;130:441-48.
Publikationen 2003
Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol. 2003;31:218-25.
Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Hacker G, Goetze K, Oostendorp R, Peschel C, Decker T. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol. 2003;122:260-268.
Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates and uses pp60c-src to mediate its mitogenicity. Blood. 2003.
Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, Rosenbrock H, Keller U, Heinzmann U, Rummeny EJ, Schlegel J, Link TM. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology. 2003;228:760-767.
Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, Peschel C, Licht T. Induction of Caspase-Dependent Programmed Cell Death in B-Cell Chronic Lymphocytic Leukemia Cells by Anti-CD22 Immunotoxins. Blood. 2003.
Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2003;101:278-85.
Drexler I, Staib C, Kastenmüller W, Stevanovic S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A. 2003;100:217-22.
Gralla R, Lichinitser M, Van D, V, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat. 2003;22:498.
Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood. 2003;102:646-51.
Gundel H, Lordick F, Brandl T, Wurschmidt F, Schussler J, Leps B, Sendler A, Mert E, Pouget-Schors D, von Schilling C, Peschel C, Sellschopp A. [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]. Z Psychosom Med Psychother. 2003;49:246-61.
Herder C, Tonn T, Oostendorp R, Becker S, Keller U, Peschel C, Grez M, Seifried E. Sustained Expansion and Transgene Expression of Coagulation Factor VIII-Transduced Cord Blood-Derived Endothelial Progenitor Cells. Arterioscler Thromb Vasc Biol. 2003.
Hsu EC, Hsi B, Hirota-Tsuchihara M, Ruland J, Iorio C, Sarangi F, Diao J, Migliaccio G, Tyrrell DL, Kneteman N, Richardson CD. Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol. 2003;21:519-25.
Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol. 2003;31:504-11.
Kremer M, Spitzer M, Mandl-Weber S, Stecker K, Schmidt B, Höfler H, Quintanilla-Martinez L, Fend F. Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest. 2003;83:107-14.
Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89:630-633.
Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol. 2003;120:1073-78.
Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo. Leukemia. 2003;17:1695-99.
Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, von Schilling C, Morris SW, Peschel C, Duyster J. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene. 2003;22:4642-47.
Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, Coutre PP, Freund M, Merx K, Paschka P, Konig H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003.
Nieder C, Licht T, Andratschke N, Peschel C, Molls M. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev. 2003;29:11-19.
Ouyang T, Bai RY, Bassermann F, Von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J Biol Chem. 2003;278:30028-36.
Ouyang T, Bai RY, Bassermann F, Von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J. Identification and characterization of a nuclear interacting partner of ALK (NIPA){pound}. J Biol Chem. 2003.
Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs. 2003;21:481-86.
Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity. 2003;19:749-58.
Ruland J, Mak TW. From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-kappaB. Semin Immunol. 2003;15:177-83.
Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor kappaB. Immunol Rev. 2003;193:93-100.
von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res. 2003;63:6395-404.
von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia. 2003;17:829-38.
von Schilling C. Immunotherapy with anti-CD20 compounds. Semin Cancer Biol. 2003;13:211-22.
Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-57.
Wohlbold L, Van Der KH, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. 2003; 102:2236-2239
Publikationen 2004
Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, Ritter M, Hochhaus A, Muller R, Eilers M, Schmidt M, Neubauer A. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 2004; 103(9):3480-3489.
Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004; 103(4):1464-1471.
Czekalla R, Fuchs M, Stolzle A, Nerlich A, Poremba C, Schaefer KL, Weirich G, Hofler H, Schneller F, Peschel C, Siewert JR, Schepp W. Peripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case report. Eur J Gastroenterol Hepatol 2004; 16(12):1391-1400.
Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M, Heinzmann U, Schlegel J, Oostendorp RA, Rummeny EJ. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging 2004; 31(9):1312-1321.
Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004; 101(29):10602-10607.
Decker T, Hipp S, Hahntow I, Schneller F, Peschel C. Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target. Br J Haematol 2004; 125(2):141-148.
Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, Peschel C, Licht T. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 2004; 103(7):2718-2726.
Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Vreckem AV, Seymour L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004; 46(3):361-368.
Fischer M, Behr T, Grunwald F, Knapp WH, Trumper L, von Schilling C. [Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma]. Nuklearmedizin 2004; 43(5):171-176.
Fleischer K, Schmidt B, Kastenmuller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. J Immunol 2004; 172(1):162-169.
Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, Peschel C, Decker T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18(4):747-755.
(12) Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thodtmann J, Lordick F. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15(3):526-536.
Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103(10):3644-3654.
Link TM, Koppers BB, Licht T, Bauer J, Lu Y, Rummeny EJ. In vitro and in vivo spiral CT to determine bone mineral density: initial experience in patients at risk for osteoporosis. Radiology 2004; 231(3):805-811.
Lordick F, Rosenberg R, Stein HJ, Peschel C, Siewert JR. [Adjuvant therapy for colon cancer]. Dtsch Med Wochenschr 2004; 129(44):2266-2371.
Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91(5):540-551.
Meyer zum Bueschenfelde CO, Unternaehrer J, Mellman I, Bottomly K. Regulated recruitment of MHC class II and costimulatory molecules to lipid rafts in dendritic cells. J Immunol 2004; 173(10):6119-6124.
Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer Drugs 2004; 15(1):15-22.
Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res 2004; 64(20):7296-7301.
Nilsson JA, Maclean KH, Keller UB, Pendeville H, Baudino TA, Cleveland JL. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol 2004; 24(4):1560-1569.
Orelio C, Harvey KN, Miles C, Oostendorp RA, van der HK, Dzierzak E. The role of apoptosis in the development of AGM hematopoietic stem cells revealed by Bcl-2 overexpression. Blood 2004; 103(11):4084-4092.
Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15(12):1773-1781.
Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, Decker T. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004; 18(12):1964-1970.
Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Gotze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Dohner K, Haas R, Dohner H. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18(11):1798-1803.
Schliep S, Decker T, Schneller F, Wagner H, Hacker G. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol 2004; 32(6):556-562.
Stahl A, Wieder H, Wester HJ, Piert M, Lordick F, Ott K, Rummeny E, Schwaiger M, Weber WA. PET/CT molecular imaging in abdominal oncology. Abdom Imaging 2004; 29(3):388-397.
Van der Kuipp H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. Leuk Res 2004; 28(4):405-408.
Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. Ann Thorac Surg 2004; 78(3):1037-1041.
von Bubnoff N, Peschel C, Duyster J. [An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]. Dtsch Med Wochenschr 2004; 129(40):2100-2103.
von Bubnoff N, Veach DR, Van Der KH, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2004.
von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2004.
Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22(5):900-908.
Kleyman MP, Pereira LA, van Zeeburg HJ, Gilfillan S, Meisterernst M, Timmers HAT. NC2alpha interacts with BTAF1 and stimulates its ATP-dependent association with TAT-binding protein. Mol Cell Biol 2004, 24(22):10072-10082.
Publikationen 2005
von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J.
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.
Leukemia. 2005 Jul 14; [Epub ahead of print]
Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C.
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Br J Cancer. 2005 Jul 25;93(2):190-4.
Bassermann F, von Klitzing C, Munch S, Bai RY, Kawaguchi H, Morris SW, Peschel C, Duyster J.
NIPA Defines an SCF-Type Mammalian E3 Ligase that Regulates Mitotic Entry.
Cell. 2005 Jul 15;122(1):45-57.
Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J.
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib.
Leukemia. 2005 Jun 30.
Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F.
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Br J Cancer. 2005 Jun 20;92(12):2129-33.
Oostendorp RAJ, Robin C, Steinhoff C, Marz S, Bräuer R, Nuber UA, Dzierzak EA, Peschel C.
Long-term maintenence of hematopoietic stem cells does not require contact with embryo-derived stromal cells in cocultures.
Stem Cells, 2005 Jun;23(6):842-51.
Lordick F, Ihbe-Heffinger A, Peschel C.
Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours
Z Gastroenterol. 2005 Apr;43(4):391-8.
Nieder C, Schneller F, Grosu AL, Peschel C, Molls M.
Radiotherapy and Chemotherapy for Myoepithelioma of the Sellar Region
Strahlenther Onkol. 2005 Apr;181(4):260-263.
von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J.
A Cell-Based Screening Strategy that Predicts Mutations in Oncogenic Tyrosine Kinases:
Implications for Clinical Resistance in Targeted Cancer Treatment.
Cell Cycle. 2005 Mar 25;4(3) [Epub ahead of print].
Urschel S, Bassermann F, Bai RY, Muench S, Peschel C, Duyster J.
Phosphorylation of Grb10 regulates its interaction with 14-3-3.
J Biol Chem. 2005 Feb 18; [Epub ahead of print].
Grundler R, Miething C, Thiede C, Peschel C, Duyster J.
FLT3-ITD and tyrosine kinase domain mutants induce two distinct phenotypes in a murine bone marrow transplant model.
Blood. 2005 Feb 17; [Epub ahead of print].
von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J.
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
Leukemia. 2005 Feb;19(2):286-7.
Ringshausen I, Peschel C, Decker T.
Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option
Leuk Lymphoma. 2005 Jan;46(1):11-9.
Ott I, Keller U, Knoedler M, Götze KS, Doss K, Fischer P, Urlbauer K, Debus G, von Bubnoff N, Rudelius M, Schömig A, Peschel C, Oostendorp RAJ.
Transplantation of endothelial-like cells expanded from CD34+ cells improve left ventricular function after experimental myocardial infarction.
FASEB J. 2005 Apr.
Daldrup-Link HE, Rudelius M, Piontek G, Metz S, Brauer R, Debus G, Corot C, Schlegel J, Link TM, Peschel C, Rummeny EJ, Oostendorp RA
Migration of Iron Oxide-labeled Human Hematopoietic Progenitor Cells in a Mouse Model: In Vivo Monitoring with 1.5-T MR Imaging Equipment
Radiology. 2005 Jan;234(1):197-205.
Oostendorp RAJ, Harvey K, Dzierzak EA.
Generation of murine stromal cell lines: models for the microenvironment of the embryonic mouse aorta-gonads-mesonephros region.
Methods Mol Biol. 2005; 290: 163-72.
Bernhard H, Schmidt B, Busch DH, Peschel C
Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapy
Methods Mol Med. 2005;109:175-84.
Publikationen 2006
Witzig R, Schonberger B, Fink U, Busch R, Gundel H, Sendler A, Peschel C, Siewert JR, Lordick F.
Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma.
Endoscopy. 2006 Nov;38(11):1122-6.
Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J.
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-{kappa}B activation and cytokine production.
Proc Natl Acad Sci U S A. 2006 Nov 9
Ringshausen I, Peschel C, Decker T.
Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.
Curr Drug Targets. 2006 Oct;7(10):1349-59.
Jost P, Peschel C, Ruland J.
The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.
Curr Drug Targets. 2006 Oct;7(10):1335-40.
Miething C, Peschel C, Duyster J.
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options.
Curr Drug Targets. 2006 Oct;7(10):1329-34.
Schmidt B, Kremer M, Gotze K, John K, Peschel C, Hofler H, Fend F.
Bone marrow involvement in follicular lymphoma: Comparison of histology and flow cytometry as staging procedures.
Leuk Lymphoma. 2006 Sep;47(9):1857-62.
Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, Ruland J.
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.
Nature. 2006 Aug 10;442(7103):651-6. Epub 2006 Jul 12
Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T.
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Br J Haematol. 2006 Jul 20;
Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Sendler A, Siewert JR, Peschel C, Lordick F.
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Ann Thorac Surg. 2006 Jul;82(1):293-7.
von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J, Stover EH, Cools J, Gilliland DG.
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
Blood. 2006 Jun 15;107(12):4970-4972.
Schwaiger M, Peschel C.
Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy.
Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 13:1-5.
von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J.
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Blood. 2006 Aug 15;108(4):1328-33. Epub 2006 Apr 13
Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, Sutter G.
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity.
Virology. 2006 Jul 5;350(2):276-88. Epub 2006 Apr 3
Bogner C, Sandherr M, Perker M, Weick K, Ringshausen I, Peschel C, Decker T.
Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
Ann Hematol. 2006 Jul;85(7):458-62. Epub 2006 Mar 15.
Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster J.
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
Leukemia. 2006 Apr;20(4):650-7.
Bogner C, Peschel C, Decker T.
Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach.
Leuk Lymphoma. 2006 Feb;47(2):195-205.
Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T.
Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.
Leukemia. 2006 Mar;20(3):514-20.
Klemm S, Gutermuth J, Hultner L, Sparwasser T, Behrendt H, Peschel C, Mak TW, Jakob T, Ruland J.
The Bcl10-Malt1 complex segregates Fc{varepsilon}RI-mediated nuclear factor {kappa}B activation and cytokine production from mast cell degranulation.
J Exp Med. 2006 Feb 20;203(2):337-47. Epub 2006 Jan 23
Publikationen 2007
Bassermann F, von Klitzing C, Illert AL, Muench S, Morris SW, Pagano M, Peschel C, Duyster J.
Multisite phosphorylation of nipa at G2/M involves cyclin B1/CDK1.
J Biol Chem. 2007 Mar 27
Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, Geigl J, Speicher MR, Ottmann O, Peschel C, Duyster J.
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4594-9. Epub 2007 Mar 5
Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, Busch DH, Bernhard H.
Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens.
J Immunol Methods. 2007 Jan 31
Jost PJ, Weiss S, Ferch U, Gross O, Mak TW, Peschel C, Ruland J.
Bcl10/Malt1 Signaling Is Essential for TCR-Induced NF-{kappa}B Activation in Thymocytes but Dispensable for Positive or Negative Selection.
J Immunol. 2007 Jan 15;178(2):953-60.
